Mashael Algethami
Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers
Algethami, Mashael; Toss, Michael S.; Woodcock, Corinne L.; Jaipal, Chandar; Brownlie, Juliette; Shoqafi, Ahmed; Alblihy, Adel; Mesquita, Katia A.; Green, Andrew R.; Mongan, Nigel P.; Jeyapalan, Jennie N.; Rakha, Emad A.; Madhusudan, Srinivasan
Authors
Michael S. Toss
Corinne L. Woodcock
Chandar Jaipal
Juliette Brownlie
Ahmed Shoqafi
Adel Alblihy
Katia A. Mesquita
Andrew R. Green
NIGEL MONGAN nigel.mongan@nottingham.ac.uk
Associate Pro-Vice Chancellorglobal Engagement
Jennie N. Jeyapalan
Emad A. Rakha
SRINIVASAN MADHUSUDAN srinivasan.madhusudan@nottingham.ac.uk
Professor of Medical Oncology
Abstract
Replication Protein A (RPA), a heterotrimeric complex consisting of RPA1, 2, and 3 subunits, is a single-stranded DNA (ssDNA)-binding protein that is critically involved in replication, checkpoint regulation and DNA repair. Here we have evaluated RPA in 776 pure ductal carcinomas in situ (DCIS), 239 DCIS that co-exist with invasive breast cancer (IBC), 50 normal breast tissue and 4221 IBC. Transcriptomic [METABRIC cohort (n = 1980)] and genomic [TCGA cohort (n = 1090)] evaluations were completed. Preclinically, RPA deficient cells were tested for cisplatin sensitivity and Olaparib induced synthetic lethality. Low RPA linked to aggressive DCIS, aggressive IBC, and shorter survival outcomes. At the transcriptomic level, low RPA tumours overexpress pseudogene/lncRNA as well as genes involved in chemical carcinogenesis, and drug metabolism. Low RPA remains linked with poor outcome. RPA deficient cells are sensitive to cisplatin and Olaparib induced synthetic lethality. We conclude that RPA directed precision oncology strategy is feasible in breast cancers.
Citation
Algethami, M., Toss, M. S., Woodcock, C. L., Jaipal, C., Brownlie, J., Shoqafi, A., …Madhusudan, S. (2023). Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers. npj Breast Cancer, 9, Article 18. https://doi.org/10.1038/s41523-023-00524-3
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 14, 2023 |
Online Publication Date | Mar 30, 2023 |
Publication Date | 2023 |
Deposit Date | Apr 9, 2023 |
Publicly Available Date | Apr 20, 2023 |
Journal | npj Breast Cancer |
Electronic ISSN | 2374-4677 |
Publisher | Nature Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 9 |
Article Number | 18 |
DOI | https://doi.org/10.1038/s41523-023-00524-3 |
Keywords | Pharmacology (medical), Radiology, Nuclear Medicine and imaging, Oncology |
Public URL | https://nottingham-repository.worktribe.com/output/19010351 |
Publisher URL | https://www.nature.com/articles/s41523-023-00524-3 |
Files
2023 NPJ Breast Cancer
(4.9 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Cell Division Cycle 6 (CDC6) is an Independent Prognostic Biomarker in Breast Cancer
(2024)
Journal Article
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Epitranscriptomic mechanisms of androgen signalling and prostate cancer
(2024)
Journal Article
The characteristics and prognostic significance of histone H1 expression in breast cancer
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search